All In Biotech

Drug Trial Radar · NCT02112994

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

A Multi-Center, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency

Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Jun 24, 2014

Primary completion

Dec 28, 2017

Study completion Dec 28, 2017

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).

Conditions

  • Lysosomal Acid Lipase Deficiency

Interventions

  • Sebelipase AlfaDrug

    IV infusion of sebelipase alfa

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)Time frame: Screening, Week 144

Locations

19 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Chicago, Illinois

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Westmead, Australia

  • Site not named

    Brussels, Belgium

  • Site not named

    São Paulo, Brazil

  • Site not named

    Halifax, Nova Scotia, Canada

  • Site not named

    Zagreb, Croatia

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Freiburg im Breisgau, Germany

  • Site not named

    Padova, Italy

  • Site not named

    Mexico City, Mexico

  • Site not named

    Amsterdam, Netherlands

  • Site not named

    Moscow, Russia

  • Site not named

    A Coruña, Spain

  • Site not named

    Barcelona, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Balcalı, Turkey (Türkiye)

  • Site not named

    Birmingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.